Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RMC-6291 |
Trade Name | |
Synonyms | RMC6291RM032|RM-032|RMC 6291 |
Drug Descriptions |
RMC-6291 is a small molecule that selectively inhibits active KRAS G12C by forming a tri-complex with KRAS G12C and cyclophilin A, potentially resulting in decreased RAS signaling and tumor cell proliferation, and reduced tumor growth (PMID: 37590355). |
DrugClasses | KRAS G12C inhibitor 34 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 | Carboplatin Pembrolizumab Pemetrexed Disodium RMC-6291 | 0 | 1 |
Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 | Cisplatin Pembrolizumab Pemetrexed Disodium RMC-6291 | 0 | 1 |
Pembrolizumab + RMC-6291 | Pembrolizumab RMC-6291 | 0 | 1 |
RMC-6236 + RMC-6291 | RMC-6236 RMC-6291 | 0 | 1 |
RMC-6291 | RMC-6291 | 0 | 1 |